SCHEMBL5054031

SCHEMBL5054031

CC(=O)N1CCN(Cc2cccc3[nH]c(-c4nn(C)c5cc(C(=O)O)ccc45)cc23)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 4/20 0.44
▸ CDK7 P50613 1/20 0.39
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SLC22A12 Q96S37 2/20 0.36
▸ KDM4C Q9H3R0 3/20 0.36
▸ LMNA P02545 3/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ ESR1 P03372 1/20 0.35
▸ ITK Q08881 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5053947 0.87 SYK (0.36) ALDH1A1MAPTSLC22A12KDM4CKMT2A
SCHEMBL5061556 0.83 CHEK1 (0.60) CHEK1CDK7
SCHEMBL5054018 0.80 KDM4C (0.37) CHEK1ALDH1A1SLC22A12KDM4CHPGD
SCHEMBL5054001 0.78 KDM4C (0.36) ALDH1A1SLC22A12KDM4CKMT2AMEN1
SCHEMBL5054165 0.78 SYK (0.37) ALDH1A1SLC22A12KDM4CITK
SCHEMBL5055543 0.78 KHK (0.38) SLC22A12KDM4CITK
SCHEMBL5054032 0.77 CHEK1 (0.57) CHEK1CDK7ALDH1A1SMN1; SMN2ITK
SCHEMBL27708447 0.75 CHEK1 (0.59) CHEK1CDK7ALDH1A1LMNASMN1; SMN2
SCHEMBL27708445 0.74 CHEK1 (0.55) CHEK1CDK7ITK
SCHEMBL5054096 0.74 CHEK1 (0.70) CHEK1CDK7ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004259-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885CDK7 43/4885ADORA2A 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback